1. Home
  2. HYPR vs BMEA Comparison

HYPR vs BMEA Comparison

Compare HYPR & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

HOLD

Current Price

$1.26

Market Cap

109.7M

Sector

Health Care

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.94

Market Cap

107.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYPR
BMEA
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.7M
107.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
HYPR
BMEA
Price
$1.26
$1.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$1.45
$9.83
AVG Volume (30 Days)
462.1K
1.9M
Earning Date
05-12-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
23.21
69.19
EPS
N/A
N/A
Revenue
$13,563,000.00
N/A
Revenue This Year
$50.75
N/A
Revenue Next Year
$29.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.22
N/A
52 Week Low
$0.53
$0.87
52 Week High
$2.22
$3.07

Technical Indicators

Market Signals
Indicator
HYPR
BMEA
Relative Strength Index (RSI) 62.52 70.53
Support Level $1.04 $1.77
Resistance Level $1.38 $2.05
Average True Range (ATR) 0.06 0.18
MACD 0.01 0.05
Stochastic Oscillator 94.04 92.99

Price Performance

Historical Comparison
HYPR
BMEA

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: